This test measures IgM antibodies against the phosphatidylserine–prothrombin complex, complementing the IgG subtype in evaluating autoimmune clotting risk.
Diagnostic Value: Elevated aPS/PT IgM levels indicate an early or transient immune response in Antiphospholipid Syndrome and related hypercoagulable states.
Clinical Significance: Testing both IgG and IgM subtypes improves detection accuracy and helps monitor disease activity or treatment response.
Symptom Correlation: Patients may present with leg swelling, shortness of breath, pregnancy complications, or neurological symptoms associated with clot formation.
Because it identifies an additional antibody class involved in coagulation disorders, aPS/PT IgM testing enhances the sensitivity of antiphospholipid evaluations.